[Effect of ebrantil, a new antihypertensive agent, on lipid metabolism and electrolyte balance].
The influence of Ebrantil on serum electrolytes, lipids, and lipoproteins was studied in 8 normotensives and 10 hypertensives. For this purpose, Ebrantil sustained-release capsules were administered after a 7-10 day diet phase concomitantly with the diet for a period of 2 weeks. Before and after the diet phase, as well as subsequent to the treatment period, laboratory parameters were determined in fasting blood. The serum levels of sodium, potassium, calcium, and magnesium were identical at all measuring times. The concentrations of triglycerides, phospholipids, total cholesterol, VLDL-, LDL-, HDL-cholesterol, and of the apolipoproteins AI, AII and B measured in all patients at the end of the treatment period deviated only slightly from those determined in the diet phase. The mean value for the arteriosclerosis index LDL/HDL decreases significantly during treatment. The results reveal that Ebrantil has no negative influence on electrolyte balance and lipometabolism.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D015243:Cholesterol, VLDL; D004573:Electrolytes / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D050356:Lipid Metabolism; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000097:blood / Q000494:pharmacology*
D000959:Antihypertensive Agents; D015243:Cholesterol, VLDL; D004573:Electrolytes; D008079:Lipoproteins, VLDL; D010879:Piperazines; D002784:Cholesterol; C015568:urapidil
Fettstoffwechsel und Elektrolyt-Haushalt unter Ebrantil, einem neuen Antihypertonikum.